Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021)

Abstract

Patients with peritoneal dissemination (PD) caused by abdominal malignancies are often associated with massive ascites, which shows extremely dismal prognosis because of the discontinuation of systemic chemotherapy mostly due to poor performance status. Many treatment methods, such as simple drainage, peritoneovenous shunting (PVS) and cell-free and concentrated reinfusion therapy (CART), have been used for symptom relief. However, the clinical efficacies of these methods have not been fully investigated yet. Recently, we developed the Clinical Practice Guideline for PD caused by various malignancies according to "Minds Clinical Practice Guideline Development Guide 2017". In this guideline, we systematically reviewed information on clinical diagnosis and treatments for PD using PubMed databases (2000 – 2020), and clarified the degree of recommendation for clinical questions (CQ). The evidence level was divided into groups by study design and quality. The literature level and a body of evidence were evaluated in reference to the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Based on the results of systematic review, the strength of the recommendations was evaluated at a consensus meeting of the Guideline Committee. This is the English synopsis of the part of treatment of malignant ascites in Clinical Practice Guideline for PD, 2021 in Japanese. The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.

Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review

“…Malignant ascites is a rare condition secondary to abdominal malignancies [ 107 ]. In an elderly adult patient diagnosed with papillary renal cell carcinoma and undergoing treatment first with pazopanib (Votrient ® ), then with sunitinib, concentrations of the administered OACD were monitored in plasma and in ascitic fluid.…”

Anatomical Targeting of Anticancer Drugs to Solid Tumors Using Specific Administration Routes: Review

“…In addition, CART often improves performance status of patients who can receive repeated I-Pr administration of PTX, which results in improved survival [ 145 ]. CART is now recommended as a treatment option for patients with malignant ascites in Japan [ 146 ].…”

Number Needed to Diagnose in Malignant Ascites: Effects of Volume, Repeating Collection, and Primary Malignancy on Diagnostic Performance in Peritoneal Fluid Cytology

“…This recommendation may not be always practical where patient and disease factors limit fluid volume and may not apply to specimens collected or divided in consecutive aliquots. As ascitic fluid can accumulate to massive volumes and recur rapidly, in both benign and malignant conditions [4, 5], collection of ascites fluid is often performed not only once but multiple times throughout an admission and throughout multiple admissions in a patient’s lifetime. This study aimed to address the issue of adequacy in peritoneal fluid cytology, not only by the volume of a single specimen but also in terms of total volumes collected daily and within an admission.…”